Richmond Pharmacology is pleased to confirm our attendance at JSCPT 2025, the Annual Meeting of the Japanese Society of Clinical Pharmacology and Therapeutics, taking place in Tokyo from 5–6 December.

Representing Richmond at JSCPT 2025:

  • Dr Jörg Täubel, Chief Executive Officer
  • Dr Ulrike Lorch, Chief Medical Director
  • Stephen Wilkinson, Business Development Manager
  • Nobuo Ittetsu, Head of Japanese Volunteer Recruitment
  • Minoru Takada, Japanese Business Development Executive

We look forward to connecting with clinical and regulatory professionals to discuss Richmond’s expertise in:

  • Early-phase and first-in-human studies
  • Bridging studies between Europe and Asia
  • Gene and RNA-based therapy development
  • Pharmacokinetics, biomarkers, and trial design
  • Cross-border collaboration in complex trials

If you’re attending JSCPT 2025 and seeking a clinical development partner, arrange a meeting with one of

Learn more: https://www.jscpt.jp/

Latest news

Patient safety is not an afterthought. Explore our new infographic!

September 17, 2025
Patient safety is not an afterthought; it is the foundation of every clinical trial.
Read more

Events

JSCPT 2025

5 – 6 December 2025
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
View event